Monte Carlo calculation of dosimetry parameters for the IR08-103Pd brachytherapy source

Design and optimizing a novel ocular plaque brachytherapy with dual-core of 103Pd and 106Ru

In recent decades, eye plaques of brachytherapy have been extensively used as primary treatment as well as a complementary treatment for ocular cancer. The purpose of this study is the development of the eye plaque brachytherapy throughout a new design of eye plaque by combining the COMS plaque and the CCB BEBIG plaque loaded by IRA1-¹⁰³Pd and ¹⁰⁶Ru, respectively. A new dual-core plaque with a diameter of 20 mm was designed in the way that the BEBIG plaque with a diameter of 20 mm loaded by ¹⁰⁶Ru plate is attached to the COMS plaque with a diameter of 20 mm loaded by 24 of IRA1-¹⁰³Pd seeds. Dose calculations for the new plaque were performed by using the MCNP5 code. Dose calculations of dual-core plaque including ¹⁰³Pd seeds (gamma) and ¹⁰⁶Ru plate (beta) were separately done for the sake of MCNP constraints in gamma and beta particle transfer simultaneously. The new dual-core plaque delivers a much higher dose rate to the tumor compared with every single plaque, while the dose rate reached to healthy tissues is slightly higher than each plaque separately. Of course, this is acceptable because the treatment time reduces and subsequently the error in radiation therapy reduces.

Dosimetric characteristics of accelerated partial breast irradiation by interstitial multicatheter brachytherapy with intraoperative free-hand implantation in the treatment of early breast cancer

Introduction

The aim of this study is to evaluate the characteristics of the dosimetry and the skin dose of interstitial brachytherapy by the use of the free‐hand implantation technique toward the treatment of early breast cancer.

Materials & Methods

Seventeen patients diagnosed with early breast cancer were selected for the study. The implantation of the catheters for postoperative interstitial brachytherapy was performed using the free‐hand technique. The total tumor dose to the tumor cavity plus 2 cm margin was 3400 cGy, twice daily for 10 fractions in 5 days. The dosage to the target and the organ at risk (OAR) were recorded for analysis. The skin dose of the patient and the phantom were measured with Gafchromic film (EBT3) and the results were compared with the skin dose calculated by the brachytherapy treatment planning system.

Results

The median conformal index is 94% (range 89%–99%), and the median homogeneity index is 71%. The median skin dose measured from the skin of the patients was 20.1% lower than the skin dose calculated from the treatment planning system and consistent with the phantom surface measurement experiment. There were no grade 3 or above acute toxicity recorded.

Conclusions

Interstitial brachytherapy by the use of the free‐hand implantation technique for early breast cancer is feasible and avoids the need for a second surgical intervention. The calculated skin dose was overestimated by at least 20%. The results of this study may help in building a modification model for the prediction of skin toxicity in any future study.

Monte Carlo calculations and experimental measurements of the TG-43U1-recommended dosimetric parameters of 125I (Model IR-Seed2) brachytherapy source

A new design of I125 (Model IR‐Seed2) brachytherapy source has been manufactured recently at the Applied Radiation Research School, Nuclear Science and Technology Research Institute in Iran. The source consists of six resin beads (0.5 mm diameter) that are sealed in a cylindrical titanium capsule of 0.7 mm internal and 0.8 mm external diameters. This work aims to evaluate the dosimetric parameters of the newly designed I125 source using experimental measurements and Monte Carlo (MC) simulations. Dosimetric characteristics (dose rate constant, radial dose function, and 2D and 1D anisotropy functions) of the IR‐Seed2 were determined using experimental measurements and MC simulations following the recommendations by the Task Group 43 (TG‐43U1) report of the American Association of Physicists in Medicine (AAPM). MC simulations were performed using the MCNP5 code in water and Plexiglas, and experimental measurements were carried out using thermoluminescent dosimeters (TLD‐GR207A) in Plexiglas phantoms. The measured dose to water in Plexiglas data were used for verification of the accuracy of the source and phantom geometry in the Monte Carlo simulations. The final MC simulated data to water in water were recommended for clinical applications. The MC calculated dose rate constant (Λ) of the IR‐Seed2 I125 seed in water was found to be 0.992±0.025 cGy h−1U−1. Additionally, its radial dose function by line and point source approximations, gL(r) and gp(r), calculated for distances from 0.1 cm to 7 cm. The values of gL(r) at radial distances from 0.5 cm to 5 cm were measured in a Plexiglas phantom to be between 1.212 and 0.413. The calculated and measured of values for 2D anisotropy function, F(r,θ), were obtained for the radial distances ranging from 1.5 cm to 5 cm and angular range of 0°‐90° in a Plexiglas phantom. Also, the 2D anisotropy function was calculated in water for the clinical application. The results of these investigations show that the uncertainty of the experimental data is within ±7% between the measured and simulated data in Plexiglas. Based on these results, the MC‐simulated dosimetric parameters of the new I125 source model in water are presented for its clinical applications in brachytherapy treatments.

PACS number(s): 87.56.bg

Dosimetric characteristics of three new design 125I brachytherapy sources

For roughly 25 years, 125I sources have been used in the treatment of various malignant diseases such as prostate cancer. Three new brachytherapy sources, IR01-125I, IR02-125I and IR03-125I, have been developed and are designed for permanent implant application. The Monte Carlo radiation transport code version MCNP 5 was used to calculate the dosimetry parameters around the sources in accordance with the updated report of the American Association of Physicists in Medicine (AAPM), Task Group No. 43. For each source, the dose rate constant Λ, the radial dose function gL(r), and the anisotropy function F(r, θ), were obtained. The results indicated a dose rate constant of 0.932 ± 0.01, 0.934 ± 0.01 and 0.939 ± 0.01 Gy h−1 U−1 for the IR01-125I, IR02-125I and IR03-125I sources respectively. With the goal of determining an optimal design for a 125I source, each seed's parameters were compared with other seeds. In this study, the optimal source IR03-125I provides the most isotropic dose distribution in water. Finally, the results for optimal source were compared with published results for those of other commercial sources.

Experimental measurements and Monte Carlo calculations for (103)Pd dosimetry of the 12 mm COMS eye plaque

Monte Carlo simulations and TLD dosimetry have been performed to determine the dose distributions along the central axis of the 12 mm COMS eye plaques loaded with IRA1-(103)Pd seeds. Several simulations and measurements have been employed to investigate the effect of Silastic insert and air in front of the eye on dosimetry results along the central axis of the plaque and at some critical ocular structures. Measurements were performed using TLD-GR200A circular chip dosimeters in a PMMA eye phantom. The central axis TLD chips locations were arranged in one central column of eye phantom, in 3 mm intervals. The off-axis TLD chips locations were arranged in three off-axis columns around the central axis column. Version 5 of the MCNP code was also used to evaluate the dose distribution around the plaque. The presence of the Silastic insert results in dose reduction of 14% at 5 mm; also about 7% dose reduction appears at the interface point, due to the air presence and lack of the scattering condition. The overall dosimetric parameters for the COMS eye plaque loaded with new palladium seeds are similar to a commercial widely used seed such as Theragenics200. As the dose calculations under TG-43 assumptions do not consider the effect of the plaque backing and Silastic insert for accurate dosimetry, it's suggested to apply the effect of the eye plaque materials and air on dosimetry results along the central axis of the plaque and at some critical ocular structures.

Thermoluminescent and Monte Carlo dosimetry of IR06-103Pd brachytherapy source

This work presents experimental dosimetry results for a new P103d brachytherapy seed, in accordance with the AAPM TG‐43U1 recommendation that all new low‐energy interstitial brachytherapy seeds should undergo one Monte Carlo (MC) and at least one experimental dosimetry characterization. Measurements were performed using TLD‐GR200A circular chip dosimeters using standard methods employing thermoluminescent dosimeters in a Perspex phantom. The Monte Carlo N‐particle (MCNP) code, version 5 was used to evaluate the dose‐rate distributions around this model P103d source in water and Perspex phantoms. The consensus value for dose‐rate constant of the IR06‐P103d source was found equal to 0.690 cG⋅h−1⋅U−1. The anisotropy function, F(r, θ), and the radial dose function, gL(r), of the seed were measured in Perspex phantom and calculated in both Perspex and liquid water phantom. The measured values were also found in good agreement with corresponding MC calculations.

PACS number: 87.53.Jw

Dosimetric characteristics of the ¹⁹²Ir high-dose-rate afterloading brachytherapy source

PURPOSE

For the treatment of some cancerous tumors using brachytherapy, an American Association of Physicists in Medicine (AAPM) Task Group No. 43U1 report recommends that the dosimetric parameters of a new brachytherapy source must be determined in two experimental and Monte Carlo theoretical methods before using each new source clinically. This study presents the results of Monte Carlo calculations of the dosimetric parameters for a Ir2.A85-2 brachytherapy source design.

MATERIALS AND METHODS

Version 5 of the (MCNP) Monte Carlo radiation transport code was used to calculate the dosimetry parameters around the source.

RESULTS

The Monte Carlo calculated dose rate constant, Λ, of the Ir2.A85-2 source was found to be 1.113 ± 0.033 cGyU(-1)h(-1). Also in this study, the line-source radial dose function, g ( l )(r) and the anisotropy function, F(r,θ), have been calculated at distances from 0.5 to 10 cm. The results of these calculations have been compared with the published data for the same source.

CONCLUSION

All the results are in good concordance with previously published data, with a few exceptions in small angles and short distances. The dosimetric parameters calculated in this work can be used as input data in a treatment planning system (TPS) for exact brachytherapy treatment planning or to verify the calculations of the TPS used in brachytherapy.